MedTrace Logo

Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis

NCT07303777 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2026-04-28

No results posted yet for this study

Summary

This is a multicenter, randomized, double-blind, placebo parallel controlled study to evaluate the preliminary efficacy, safety, and PopPK profile of ABP-745 in patients with ASCVD. Efficacy of ABP-745 in reducing atherosclerotic plaque compared with placebo will be evaluated in participants with ASCVD. The primary efficacy measurement will be assessed at 52W of treatment.

Conditions

  • Atherosclerosis Cardiovascular Disease
  • ASCVD
  • ASCVD Management

Interventions

DRUG

ABP-745 Dose A

ABP-745 Dose A - tablets (PO), low dose , QD

DRUG

Placebo

ABP-745 placebo - tablets (PO), non-active,QD

DRUG

ABP-745 Dose B

ABP-745 Dose B - tablets (PO), Midum dose, QD

DRUG

ABP-745 Dose C

ABP-745 Dose C - tablets (PO), High dose, QD

Sponsors & Collaborators

  • Atom Therapeutics Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-23
Primary Completion
2028-01-31
Completion
2028-04-30
FDA Drug
Yes

Countries

  • United States
  • Australia
  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07303777 on ClinicalTrials.gov